Contineum Therapeutics (CTNM) Depreciation & Amortization (CF) (2023 - 2026)
Contineum Therapeutics (CTNM) recorded quarterly Depreciation & Amortization (CF) of $83000.0 in Q1 2026, up 33.87% quarter-over-quarter from $62000.0 in Q4 2025, and up 6.41% on a YoY basis from $78000.0 in Q1 2025.
Contineum Therapeutics (CTNM) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $83000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 6.41% year-over-year to $83000.0; the TTM figure through Mar 2026 stood at $305000.0 (down 3.79% YoY), while the FY2025 annual figure was $300000.0, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) was $83000.0 for Q1 2026 at Contineum Therapeutics, up from $62000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $117000.0 in Q4 2024 to a low of $37000.0 in Q4 2023.
- Historically, Depreciation & Amortization (CF) has averaged $67538.5 across 4 years, with a median of $62000.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) soared 216.22% in 2024, then plunged 47.01% in 2025.
- A 4-year view of Depreciation & Amortization (CF) shows it stood at $37000.0 in 2023, then jumped by 216.22% to $117000.0 in 2024, then slumped by 47.01% to $62000.0 in 2025, then jumped by 33.87% to $83000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $83000.0 (Q1 2026), $62000.0 (Q4 2025), and $81000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Contineum Therapeutics | 423.05 Mn | 423.05 Mn | - | 83,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83,000.00 |
| Mar 31, 2026 | 83,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 79,000.00 |
| Jun 30, 2025 | 79,000.00 |
| Mar 31, 2025 | 78,000.00 |
| Mar 31, 2025 | 78,000.00 |
| Dec 31, 2024 | 117,000.00 |
| Dec 31, 2024 | 117,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Jun 30, 2024 | 60,000.00 |
| Jun 30, 2024 | 60,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Dec 31, 2023 | 37,000.00 |
| Dec 31, 2023 | 37,000.00 |